3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
72
Burkitt Lymphoma
43
Neoplasm, Residual
18
Leukemia
15
Recurrence
14
Lymphoma, Non-Hodgkin
8
Leukemia, Biphenotypic, Acute
8
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoproliferative Disorders
6
Lymphatic Diseases
5
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, B-Cell
4
Lymphoma
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia, Lymphoid
4
Immunoproliferative Disorders
4
Neoplasms
3
Blast Crisis
3
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Myeloid
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hematologic Neoplasms
2
Down Syndrome
2
Bites and Stings
2
Sarcoma, Myeloid
1
Philadelphia-Negative ALL
1
Philadelphia Chromosome
1
Interventions
Imatinib Mesylate
14
Dasatinib
5
nilotinib
4
Cyclophosphamide
4
fludarabine
3
bosutinib
3
Vincristine
3
Methotrexate
3
Dexamethasone
3
Cytarabine
3
peginterferon alfa-2a
2
fludarabine phosphate
2
asciminib
2
Prednisone
2
Daunorubicin
2
Azacitidine
2
Acetaminophen
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
venetoclax
1
thymoglobulin
1
ponatinib
1
olverembatinib
1
flumatinib
1
blinatumomab
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Tacrolimus
1
Rituximab
1
Prednisolone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Philadelphia Chromosome
×
blinatumomab
×
Clear all
NCT06220487
2024-01-24
ABC
Nanfang Hospital, Southern Medical University
Phase 2
Recruiting
67 enrolled